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ABSTRACT
Purpose: The present study assessed the role of an amino acid-based formula (AAF) in the 
growth of infants with cow's milk protein allergy (CMPA).
Methods: Non-breastfed, term infants aged 0–6 months with symptoms suggestive of CMPA 
were recruited from 10 pediatric centers in China. After enrollment, infants were started 
on AAF for two weeks, followed by an open food challenge (OFC) with cow's milk-based 
formula (CMF). Infants with confirmed CMPA remained on AAF until 9 months of age, in 
conjunction with a cow's milk protein-free complementary diet. Body weight, length, and 
head circumference were measured at enrollment and 9 months of age. Measurements were 
converted to weight-for-age, length-for-age, and head circumference-for-age Z scores (WAZ, 
LAZ, HCAZ), based on the World Health Organization growth reference.
Results: Of 254 infants (median age 16.1 weeks, 50.9% male), 218 (85.8%) were diagnosed 
with non-IgE-mediated CMPA, 33 (13.0%) tolerated CMF, and 3 (1.2%) did not complete 
the OFC. The mean WAZ decreased from 0.119 to −0.029 between birth and enrollment 
(p=0.067), with significant catch-up growth to 0.178 at 9 months of age (p=0.012) while being 
fed the AAF. There were no significant changes in LAZ (0.400 vs. 0.552; p=0.214) or HCAZ 
(−0.356 vs. −0.284; p=0.705) from the time of enrollment to age 9 months, suggesting normal 
linear and head growth velocity.
Conclusion: The amino acid-based study formula, in conjunction with a cow's milk protein-
free complementary diet, supported normal growth till 9 months of age in a cohort of 
Chinese infants with challenge-confirmed non-IgE-mediated CMPA.
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INTRODUCTION
Cow's milk protein allergy (CMPA) is the most common food allergy in infancy [1,2]. The 
reported worldwide prevalence of CMPA varies between 0.7 to 2.7% [2-5]. Symptoms of 
immediate-type CMPA (IgE-mediated) include urticaria, lip swelling, facial angioedema, 
and in extreme cases, anaphylaxis [6]. By contrast, non-IgE-mediated CMPA presents in 
infancy with a range of gastrointestinal and systemic manifestations, including vomiting 
or regurgitation, diarrhea, rectal bleeding, feeding difficulties, persistent crying, and sleep 
problems [7]. Conditions with a mixed IgE- and non-IgE-mediated etiology, such as atopic 
eczema and eosinophilic esophagitis, are also frequently associated with CMPA [8-10].
The treatment of CMPA relies on strict dietary elimination of cow's milk protein (CMP) from 
the infant's diet [11]. In symptomatic breastfed infants, a maternal elimination diet may also 
be helpful [12]. In formula-fed infants, the management of CMPA generally involves the use 
of an extensively hydrolyzed formula (EHF) or an amino acid-based formula (AAF) [11,13]. 
While EHF is considered the first-line formula of choice in the management of infants with 
mild to moderate CMPA symptoms, AAF is generally prescribed to infants with moderate 
to severe symptoms, including those with a history of anaphylaxis, growth failure, or 
eosinophilic esophagitis [11,14,15].
Several studies have suggested that, compared to healthy children, growth in children with 
food allergies is often impaired, and the etiology is multifactorial [16,17]. Causative factors 
include prolonged dietary restrictions as part of a single or multiple allergen avoidance, 
associated feeding difficulties, and atopic comorbidities, rather than differences in energy 
expenditure or nutritional needs [18-21]. Moreover, infants and young children receiving an 
unsupervised cow's milk exclusion diet have an increased risk of micronutrient deficiencies, 
mainly due to insufficient iron, calcium, and vitamin B12 intake [17,22].
Growth studies for AAF have traditionally been conducted in healthy infants between 0 
and 4 months of age to assess the growth parameters in a well-defined population that is 
fed exclusively with the study formula, either comparing growth to breastfed infants or a 
control group receiving another reference formula [23-26]. Several growth studies have been 
conducted in the target population of infants with CMPA [27-30]. While this approach may 
be more relevant clinically, the interpretation may be confounded by age and complementary 
diet. Overall, these studies have shown that AAF supports adequate growth and nutrition 
in children with CMPA. Data on long-term growth outcomes in infants with CMPA who 
are managed with an AAF are limited, highlighting a need for further studies in the target 
population [29]. The abovementioned studies were conducted in North America or Europe, 
and no dedicated growth studies are currently available for Asian infants. As part of a 
validation study for the Cow's Milk-related Symptom Score (CoMiSS™) [31], we prospectively 
evaluated anthropometric parameters in a cohort of Chinese infants with challenge-
confirmed CMPA. The objective of the present study was to assess whether AAF supports 
normal growth in infants with CMPA up to 9 months of age, in conjunction with a CMP-free 
complementary diet.
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MATERIALS AND METHODS
Non-breastfed infants aged 0–6 months with symptoms suggestive of CMPA (e.g., eczema, 
irritability, feeding problems, vomiting/regurgitation, persistent diarrhea, rectal bleeding) were 
recruited from 10 clinical centers in China. After a baseline assessment, the infants were started 
on a strict CMP-free elimination diet with an AAF (Alfamino®; Nestlé Health Science, Vevey, 
Switzerland) for two weeks. In infants above 4 months of age, a CMP-free complementary 
diet was allowed during the trial. After 2 weeks on the elimination diet, infants underwent 
a standardized open food challenge (OFC) with a cow's milk-based infant formula (CMF, 
Nestlé NAN1®; Nestlé Nutrition) [32]. Infants who developed clinical symptoms during the 
challenge with CMF were diagnosed with CMPA and were offered to remain on the AAF until 9 
months of age. Infants who did not have symptoms on the Day 1 of OFC in the hospital, were 
subsequently assessed by a two-week home challenge with CMF. Infants who reacted during 
the home challenge phase were reviewed, and a diagnosis of CMPA was made if symptoms were 
consistent. The parents of these infants were advised to recommence AAF feeding. Infants 
who passed both the hospital and home challenges without adverse symptoms returned to an 
unrestricted diet and were discharged from the study.
Weight, length, and head circumference (HC) were measured at enrollment and final follow-
up at around 9 months of age. In addition, birth weight and length were also documented. 
Body weight was measured on calibrated digital scales, with the infant unclothed and 
recorded to the nearest 5 grams. Length was measured in a supine position on standardized 
length boards and recorded to the nearest 1 millimeter (mm). HC was measured with a 
non-elastic tape and recorded to the nearest 1 mm. Weight-for-age, length-for-age, and head 
circumference-for-age Z scores (WAZ, LAZ, and HCAZ) were calculated based on the World 
Health Organization (WHO) growth reference. Descriptive statistics (percentage, mean, 
median, standard deviation, and 95% confidence intervals) were used to summarize the data.
Study formula
The study AAF was a nutritionally complete powdered infant formula containing amino 
acids (protein equivalent 1.9 g/100 mL), carbohydrates (7.9 g/100 mL), fats (3.4 g/100 mL, 
24% medium chain triglycerides [MCT] of total fat content), vitamins, minerals, trace 
elements, long-chain polyunsaturated fatty acids, arachidonic acid (7.0 mg/100 mL), and 
docosahexaenoic acid (7.0 mg/100 mL). A previous clinical trial had confirmed that the 
study formula was hypoallergenic and suitable for the nutritional management of infants 
with CMPA [33]. During the study period, the formula was prepared by the infant's caregiver 
according to standard instructions provided on the container.
Open oral food challenge procedure
The open oral food challenge was performed in the hospital on Day 1, followed by an open 
home challenge for 2 weeks, if tolerated [32]. The hospital challenge was supervised by a 
medically qualified study investigator. All investigators were trained in the food challenge 
procedures. This training included watching a detailed training video in Chinese. The 
OFC followed a standardized dose escalation of CMF with careful documentation of any 
clinical symptoms that developed during the challenge period. The following doses of CMF 
were administered during the OFC: initial test dose of one drop on the lip of the infant; 
if no reaction was observed after 15 minutes, then 0.5 mL was given orally. If no reaction 
was observed after 30 minutes, the following oral doses were administered at 30 minutes 
intervals: 1 mL, 3 mL, 10 mL, 30 mL, 50 mL, and 100 mL (maximum cumulative dose: 194.5 
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mL), based on the tolerance of the infant. The challenge was categorized as ‘positive’ or 
‘negative’ by the investigator according to pre-defined end criteria, based on the observed 
symptoms. The OFC was considered positive in the presence of immediate symptoms 
(vomiting, urticaria, facial angioedema, wheeze, or stridor) during Day 1 in hospital or 
delayed-onset symptoms (vomiting, increased regurgitation, persistent diarrhea, increased 
eczema, or irritability/persistent crying) at any time during the home challenge phase of 
two weeks [32]. Parents were asked to report any possible clinical reaction during the home 
challenge. The reactions were then reviewed by the investigator team. In case of a positive 
OFC with verified symptoms attributed to CMPA, infants were diagnosed with CMPA and 
remained on AAF. Infants who tolerated CMF during the challenges, in hospital and at home, 
were discharged from the study.
Safety data
Adverse events (AEs), serious and non-serious, during the study period were notified 
by the investigators and coded by diagnosis, severity, date of onset, and resolution. The 
investigators also assessed the causality of these AEs in relation to the study formula.
Ethics approval, study sponsorship, and oversight
The present study was approved by the Medical Ethics Committee of Hunan Children's 
Hospital, Hunan, China (HCHLL-2016-016). The overall conduct of the study was managed 
and supervised by a contract research organization (CRO), George Clinical, Sydney, Australia. 
The CRO monitored the clinical site set-up, investigator training, adverse event reporting, 
and data management. Independent statistical analysis was performed using Cytel, 
Cambridge, MA, USA. The study was sponsored by Nestlé Health Science, Vevey, Switzerland 
and registered on ClinicalTrials.gov (NCT03004729) prior to enrollment of the first patient.
RESULTS
Of the 301 infants screened, 254 progressed to the OFC (median age, 16.1 weeks; 150 
[59.1%] male). One family withdrew before and 46 families withdrew during the AAF trial. 
The reasons for withdrawal were not consistently recorded. Infants presented with a range 
of symptoms, suggestive of non-IgE-mediated CMPA, and none of the infants presented 
with immediate symptoms. Atopic dermatitis and rectal bleeding were the most common 
presentations at enrollment. The clinical features at enrollment of the 254 infants who 
participated in the OFC are summarized in Table 1.
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Table 1. Clinical presentation of infants with suspected cow's milk protein allergy
Clinical presentation n %
Atopic dermatitis 137 53.9
Rectal bleeding 39 15.4
Persistent diarrhoea 27 10.6
Regurgitation/vomiting 24 9.4
Constipation 9 3.5
Persistent crying/irritability 7 2.8
Poor weight gain 5 2.0
Respiratory symptoms 3 1.2
Feeding difficulties 1 0.4
Other/not documented 2 0.8
Total 254 100.0
Food challenge outcomes
Of the 254 infants who completed the OFC, 184 (72.4%) developed symptoms during the 
4-hour hospital challenge on Day 1, and an additional 34 (13.4%) reacted during the home 
challenge. In total, 218 (85.8%) infants were diagnosed with CMPA. The study flow is 
summarized in Fig. 1.
Thirty-seven percent of infants had reactions involving multiple systems. The median 
eliciting dose of CMF was 3 mL (range 1–100), with significant variation across the clinical 
centers. Reactions during the OFC were generally mild to moderate in severity and the 
majority of reactions (174/184; 95%) included cutaneous manifestations, such as urticaria, 
increased redness/rash, or increased eczema. Thirty-eight (21%) infants presented with 
immediate respiratory reactions (persistent sneezing, cough, wheeze), and 29 (16%) had 
gastrointestinal reactions (nausea, food refusal, vomiting, diarrhea, or rectal bleeding).
Of the 70 infants who passed the OFC in the hospital, 67 proceeded with the 2-week home 
challenge, and three families withdrew from the study. Of these, 34 had clinical reactions that 
were deemed to be due to CMPA by the investigator. Twenty-two infants reacted during the 
first week and 12 infants during the second week of the home challenge. Reactions included 
exacerbation of eczema (n=26), recurrence of rectal bleeding (n=4), and frequent regurgitation 
(n=1). The reason for a positive home challenge was not documented in three infants.
Anthropometric measurements
Growth data were available for 217 of the 218 infants with CMPA. Of these, 126 (58.1%) were 
male. Age-adjusted mean Z scores for body weight, length, and HC calculated according to 
the WHO growth reference, confirmed that, as a group, infants maintained normal growth 
velocity from enrollment to 9 months of age (Fig. 2). The group means for WAZ, LAZ, and 
HCAZ tracked close to 0, and the mean of differences changed by less than 0.25 Z scores 
from enrollment to final visit (WAZ +0.207, LAZ +0.152, HCAZ +0.072) (Table 2).
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Fig. 1. Study flow chart. 
AAF: amino acid-based formula, CMPA: cow's milk protein allergy.
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Fig. 2. (A, B) Mean weight/weight-for-age Z score (WAZ) and length/length-for-age Z score (LAZ) from birth to 9 months in 218 infants with challenge-confirmed 
cow's milk protein allergy. Error bars indicate the 95% confidence intervals for WAZ and LAZ. p-values are provided for paired t-test comparisons between birth 
and enrollment, as well as enrollment to final follow-up at 9 months of age.
Table 2. Anthropometric measurements of 218 infants with open food challenge-confirmed cow's milk protein allergy
Time point N Age (wk) Weight (kg) WAZ Length (cm) LAZ HC (cm) HCAZ
Total cohort
Birth 217 0 3.375±0.457 0.119±0.94 50.1±1.58 0.269±0.84 ND ND
Enrollment 217 15.6±6.11 6.446±1.430 −0.029±1.35 62.6±4.63 0.400±1.49 40.1±2.21 −0.356±1.37
Final visit 211 40.0±2.85 8.923±1.251 0.178±1.25 72.7±3.00 0.552±1.36 44.2±1.63 −0.284±1.25
Male infants
Birth 126 0 3.423±0.459 0.115±0.93 50.2±1.52 0.187±0.80 ND ND
Enrollment 126 16.1±5.69 6.802±1.409 0.025±1.43 63.4±4.30 0.301±1.56 40.6±2.13 −0.406±1.44
Final visit 120 39.9±2.68 9.143±1.336 0.113±1.38 73.0±3.02 0.360±1.38 44.5±1.72 −0.455±1.34
Female infants
Birth 91 0 3.308±0.449 0.123±0.97 49.9±1.63 0.383±0.88 ND ND
Enrollment 91 14.9±6.63 5.953±1.314 −0.103±1.24 61.5±4.87 0.538±1.39 39.4±2.13 −0.285±1.28
Final visit 91 40.2±3.07 8.633±1.067 0.264±1.04 72.4±2.95 0.804±1.30 43.8±1.43 −0.059±1.09
Values are presented as mean±standard deviation.
WAZ: weight-for-age Z score, LAZ: length-for-age Z score, HC: head circumference, HCAZ: head circumference-for-age Z score, ND: no data.
Overall, WAZ decreased from 0.119 to −0.029 between birth and enrollment (p=0.067) and 
increased from −0.029 to 0.178 (p=0.012) between enrollment and final visit at 9 months of 
age. The WAZ changes were greatest in female infants, in whom the mean WAZ decreased 
significantly from 0.123 to −0.103 (p=0.044) between birth and enrollment, with subsequent 
catch-up growth from −0.103 to 0.264 (p=0.002) between enrollment and 9 months. WAZ 
scores at birth and 9 months were similar (0.123 vs. 0.264; p=0.225). For male infants, there 
were no significant differences in WAZ between the time points (Fig. 2A).
LAZ scores for the entire cohort of infants with CMPA remained similar from enrollment to 
9 months (0.400 vs. 0.552; p=0.214). However, in female infants, LAZ increased significantly 
from enrollment to final visit (0.538 vs. 0.804; p=0.037); there was no significant change in 
the male cohort. Furthermore, there were no significant differences in LAZ from birth to 
enrollment (0.269 vs. 0.400; p=0.147). There was a small but statistically significant increase 
in LAZ from birth to 9 months (from 0.269 to 0.552; p=0.003). This increase was mainly seen 
in the female cohort (0.383 vs. 0.804; p=0.002), whereas no such trend was observed in the 
male infants (0.187 vs. 0.360; p=0.205) (Fig. 2B).
There were no significant differences in the mean HCAZ scores between enrollment and final 
visit (−0.356 vs. −0.284; p=0.705). The mean HCAZ scores for male infants changed non-
significantly from −0.406 to −0.455 (p=0.379), and for female infants increased slightly from 
−0.286 to −0.059 (p=0.133).
Safety data
There were 13 severe adverse events (SAEs) requiring hospitalization in 11 infants 
(bronchopneumonia/lower respiratory tract infection, n=8; gastroenteritis, n=2; Coxsackie 
virus infection, n=1; Kawasaki disease, n=1; cardiac malformation, n=1). All SAEs were 
deemed to be unrelated to the study formula. In addition, there were 207 non-serious AEs 
in 100 infants. These reported AEs were due to a range of conditions, including respiratory 
infection, 93 (44.9%); febrile illness/viral infection, 43 (20.8%); gastroenteritis/acute 
diarrhea, 24 (11.6%); functional problems (crying, dyspepsia, regurgitation, or constipation), 
18 (8.7%); eczema flare/rash, 16 (7.7%); and in 13 (6.3%) by less common conditions. Four 
(1.9%) AEs were attributed as ‘related’ to the study product by the investigators (dyspepsia, 
n=1; eczema, n=1; perirectal abscess, n=1; diarrhea, n=1).
DISCUSSION
Our study examined the growth parameters in a large cohort of infants with challenge 
confirmed CMPA. To the best of our knowledge, this is the first such study performed 
in Chinese infants with CMPA. The diagnosis was established by 2-weeks strict CMP 
elimination while being fed an AAF, followed by a standardized OFC in the hospital and a 
2-week open challenge at home, in this study. A diagnosis of CMPA was made in over 85% of 
the participating infants. Based on the spectrum of symptoms at enrollment, these infants 
suffered from non-IgE-mediated CMPA.
The group means of age-adjusted Z scores for weight, length, and HC at birth, enrollment 
at around 16 weeks of age, and the final visit at 9 months of age were close to 0. The 
anthropometric Z scores progressed in parallel with the 0 line, with changes in growth 
parameters within +0.25 standard deviations. The WAZ at the time of enrollment trended 
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toward a slightly lower Z score, compared to birth, indicating mild weight loss secondary to 
CMPA. This decrease in WAZ was significant in the female infant cohort, who also achieved 
significant catch-up growth with the study formula by 9 months of age. This was associated 
with a small but significant increase in linear growth (LAZ) in female infants. There were 
no significant changes in WAZ, LAZ, or HCAZ in male infants in the present study. These 
findings strongly suggest that, as a group, infants maintained normal growth velocity, as well 
as linear and head growth velocity while being fed the study AAF, in conjunction with a CMP-
free complementary diet.
The findings of the present study are in line with other studies in infants with CMPA that have 
also confirmed adequate growth while being fed an AAF [26-30]. In contrast, a recent review of 
growth patterns in healthy infants aged 0–4 months raised concerns that some hypoallergenic 
formulas may be associated with suboptimal growth [34]. This was mainly attributed to a 
high content of MCT exceeding 50% of total fat in some AAF or EHF products [34]. MCT are 
included in EHF and AAF to address possible fat malabsorption [35]. While MCTs are readily 
absorbed and utilized in the liver and muscle, they are minimally stored in fat tissue, which 
may explain the poor weight gain observed with high-MCT formulas in the first months of life 
[36,37]. The AAF used in the current study has an MCT content of 24%, and no evidence of 
growth impairment was observed in our cohort. However, our study design did not allow for a 
detailed assessment of the growth parameters in the first month of life.
The provision of adequate amounts of dietary protein is a prerequisite for normal growth 
during infancy. Most AAF contain relatively high levels of protein equivalent in the form 
of free amino acids, which exceeds the protein content in breast milk or standard infant 
formula. The rationale for this increased concentration is that not all amino acids may 
be absorbed and used as a source of nutrition. A high protein content in standard infant 
formulas has been linked to an increased risk of obesity in later childhood, but it remains 
unclear whether this also applies to AAF [38,39]. A systematic review did not detect evidence 
of accelerated growth in infants fed with an AAF [34]. In addition, a growth study in infants 
with CMPA managed with an AAF demonstrated normal growth till 12 months of age [29]. 
The present study provides additional normal growth data in infants fed an AAF up to 9 
months of age, and no excessive weight gain was observed in our cohort.
The present study has several limitations. Data were collected as part of a large validation 
study of a possible diagnostic tool for CMPA, and growth was not the primary outcome. As a 
result, growth data were systematically collected only during the enrollment and study exit. 
In addition, formula volume intake and the contribution of the complementary diet were not 
documented. A further limitation is that the diagnosis of CMPA was not made by a double-
blinded, placebo-controlled food challenge, which may have led to an overestimation of the 
rate of CMPA in our study. Despite these limitations, our study provides real-life growth data 
for a cohort of infants with challenge-confirmed CMPA.
In conclusion, our study demonstrates that Chinese infants with challenge-confirmed, non-
IgE-mediated CMPA achieved normal weight gain, linear growth, and head growth while 
being fed the amino acid-based study formula, together with a CMP-free elimination diet, 
during the first 9 months of life. We did not observe evidence of excessive weight gain in our 
cohort, and we recommend further studies to assess the long-term effects of AAF on growth 
and body composition.
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